Research Article
Overexpression of MAL2 Correlates with Immune Infiltration and Poor Prognosis in Breast Cancer
Table 2
Clinical characteristics of TCGA breast cancer cohort.
| Characteristics | Number of sample size (%) |
| Age | <40 | 75 (6.88) | ≥40 | 1015 (93.12) |
| Gender | Female | 1079 (98.90) | Male | 12 (1.10) |
| Stage | I | 182 (16.70) | II | 620 (56.88) | III | 249 (22.84) | IV | 21 (1.93) | X | 18 (1.65) |
| T classification | T1 | 280 (25.69) | T2 | 630 (57.80) | T3 | 138 (12.66) | T4 | 39 (3.58) | TX | 3 (0.28) |
| M classification | M0 | 900 (82.57) | M1 | 22 (2.02) | MX | 168 (15.41) |
| N classification | N0 | 484 (44.40) | N1 | 390 (35.78) | N2 | 180 (16.51) | N3 | 27 (2.48) | NX | 9 (0.83) |
| ER status | Negative | 236 (21.65) | Positive | 805 (73.85) | Unknown | 49 (4.50) | PR status | 343 (31.47) | Negative | 695 (63.76) | Positive | 52 (4.77) | Unknown | 559 (51.28) | HER2 status | 163 (14.95) | Negative | 368 (33.76) | Positive | 236 (21.65) | Unknown | 805 (73.85) | Vital status | Living | 941 (86.33) | Deceased | 149 (13.67) |
| MAL2 expression | High | 545 (50.00) | Low | 545 (50.00) |
|
|
NA, not available.
|